Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 3116903 approvals1 trials

CJ Bioscience

Official website

CJ Bioscience develops microbiome drugs CJRB-101, CJRB-201 via AI platform Ez-Mx®, and runs gut-health services GUT INSIDE, SMILE GUT.

As of 2026-10-10, CJ Bioscience has 3 Korean MFDS device approvals, 34 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2009 and listed on KOSDAQ in 2019, CJ Bioscience is a microbiome-focused bioscience company. Using its AI-based microbiome analysis platform Ez-Mx®, it is developing CJRB-101 for lung and head-and-neck cancer in combination with Keytruda, and CJRB-201 for inflammatory bowel disease, alongside an EzBioCloud-based NGS/BI solution and gut-health services GUT INSIDE and SMILE GUT. The company has built a Gut Microbiome Index (GMI) based on more than 140,000 microbiome data points.

Products & technology

  • Ez-Mx®AI-based microbiome drug discovery platform
  • EzBioCloudMicrobial genome NGS/BI integrated analysis solution
  • GUT INSIDEGut microbiome health analysis service for medical institutions
  • SMILE GUTConsumer-facing gut health diagnostic service

Regulatory approvals

data.go.kr

3 Korean MFDS device approvals · 2018–2025

  • MFDSSpecimen transport media2025-10-01
    Product approval · Class 1체외 제신 25-1320 호
  • MFDSSpecimen transport media2019-05-07
    Product approval · Class 1체외 제신 19-571 호
  • MFDSOther reagent of sample preparation kit2018-09-21
    Product approval · Class 1체외 제신 18-1279 호

Clinical trials

data.go.kr

1 MFDS clinical trial authorisations · 2023 (Phase 1/2 1)

  • Phase 1/2CJRB-1012023-06-15

    6 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

CJRB-101 · 폐암, 두경부암 · 임상(키트루다 병용요법, 미국·한국 동시 진행) · Microbiome combination candidate identified via Ez-Mx® platform, combined with Keytruda

CJRB-201 · 염증성 장질환(IBD) · 전임상(동물실험 완료, 임상 진입 목표) · Demonstrated antibody-level anti-inflammatory effect in animal studies

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 24 more publications

Patents

KIPRIS · applicant-matched
Show 50 more patents

AI reads

MAA server logs · IP-verified
51
Times AI engines pulled CJ Bioscience's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

4
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

47
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

11
live 0
Last 7 days
41
live 2
Last 30 days
51
live 4
All time
  • OpenAIChatGPT-Userlive4
  • OpenAIOAI-SearchBot38
  • GoogleGoogleOther3
  • PerplexityPerplexityBot3
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 25, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for CJ Bioscience and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Aimed Bio Inc.1 shared

KOSDAQ-listed ADC oncology biotech that has out-licensed pipeline candidates to Biohaven, SK Plasma, and Boehringer Ingelheim.

Ensol Biosciences Inc.1 shared

Ensol Biosciences is a KONEX-listed biotech developing short peptide therapeutics that modulate protein-protein interactions (PPI).

Synergy Innovation Co., Ltd.1 shared

Synergy Innovation, founded in 1998 and KOSDAQ-listed in 2004, manufactures and sells microbial culture media.

Gencurix Inc.1 shared

Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.

ASTA Co., Ltd.1 shared

Founded in 2006 and KOSDAQ-listed in 2017, ASTA develops MALDI-TOF mass spectrometry diagnostic and industrial systems.

Median Diagnostics Inc.1 shared

Founded in 1999 and listed on KONEX in 2017, Median Diagnostics develops and manufactures immunoassay, molecular, and point-of-care in vitro diagnostic kits for animal diseases.

Xcell Therapeutics Inc.1 shared

Xcell Therapeutics develops the domestically produced CellCor™ cell culture media series for cell and gene therapy manufacturing.

PCL. Inc1 shared

KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.

BIONEERCORPORATION1 shared

Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.

SEEGENE, INC.1 shared

Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.

BIODYNE CO., LTD.1 shared

Founded in 1999 and KOSDAQ-listed in 2021, BIODYNE develops liquid-based cytology (LBC) devices and diagnostic reagent kits.

Genomictree Inc.1 shared

Cancer molecular diagnostics company behind the EarlyTect-C stool-based colorectal cancer test using the SDC2 methylation biomarker.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition